MA55486A - Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial - Google Patents

Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial

Info

Publication number
MA55486A
MA55486A MA055486A MA55486A MA55486A MA 55486 A MA55486 A MA 55486A MA 055486 A MA055486 A MA 055486A MA 55486 A MA55486 A MA 55486A MA 55486 A MA55486 A MA 55486A
Authority
MA
Morocco
Prior art keywords
treatment
tyrosine kinase
kinase inhibitors
urothelial carcinoma
fgfr tyrosine
Prior art date
Application number
MA055486A
Other languages
English (en)
Inventor
Porre Peter Marie Z De
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA55486A publication Critical patent/MA55486A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA055486A 2019-03-29 2020-03-27 Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial MA55486A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19166429 2019-03-29
US201962833395P 2019-04-12 2019-04-12

Publications (1)

Publication Number Publication Date
MA55486A true MA55486A (fr) 2022-02-09

Family

ID=69954076

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055486A MA55486A (fr) 2019-03-29 2020-03-27 Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial

Country Status (15)

Country Link
US (1) US20220175768A1 (fr)
EP (2) EP3946340A1 (fr)
JP (2) JP2022527482A (fr)
KR (1) KR20210143878A (fr)
CN (1) CN113645975A (fr)
AU (1) AU2020253054B2 (fr)
BR (1) BR112021019203A2 (fr)
CA (1) CA3130773A1 (fr)
IL (1) IL286727A (fr)
JO (1) JOP20210260A1 (fr)
MA (1) MA55486A (fr)
MX (1) MX2021011943A (fr)
PH (1) PH12021552352A1 (fr)
SG (1) SG11202109854RA (fr)
WO (1) WO2020201138A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021339962A1 (en) * 2020-09-14 2023-05-25 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
EP4415692A1 (fr) 2021-10-12 2024-08-21 TARIS Biomedical LLC Formulations d'erdafitinib et systèmes d'administration intravésicale
WO2023159216A1 (fr) 2022-02-18 2023-08-24 Taris Biomedical Llc Formulations d'erdafitinib et systèmes osmotiques pour administration intravésicale
CN116106240B (zh) * 2022-12-26 2025-11-07 华中农业大学 一种尿液酪氨酸检测体系、检测方法及检测试剂盒
AU2024220896A1 (en) 2023-02-13 2025-10-02 Taris Biomedical Llc Erdafitinib for intravesical administration for use in the treatment of bladder cancer
CN120731077A (zh) 2023-02-17 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (fr) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
NZ563692A (en) 2005-05-23 2011-04-29 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
UA122564C2 (uk) 2014-09-26 2020-12-10 Янссен Фармацевтика Нв Використання панелі мутантних генів fgfr для ідентифікації пацієнтів із раковим захворюванням, які піддаються лікуванню інгібітором fgfr
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer

Also Published As

Publication number Publication date
MX2021011943A (es) 2021-11-03
US20220175768A1 (en) 2022-06-09
WO2020201138A1 (fr) 2020-10-08
SG11202109854RA (en) 2021-10-28
EP4548935A3 (fr) 2025-08-06
EP3946340A1 (fr) 2022-02-09
IL286727A (en) 2021-10-31
JP2026048748A (ja) 2026-03-17
CA3130773A1 (fr) 2020-10-08
AU2020253054B2 (en) 2026-01-08
KR20210143878A (ko) 2021-11-29
EP4548935A2 (fr) 2025-05-07
BR112021019203A2 (pt) 2021-11-30
AU2020253054A1 (en) 2021-09-30
JP2022527482A (ja) 2022-06-02
CN113645975A (zh) 2021-11-12
JOP20210260A1 (ar) 2023-01-30
PH12021552352A1 (en) 2022-09-05

Similar Documents

Publication Publication Date Title
MA55486A (fr) Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial
MA52780A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA52564A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3397963A4 (fr) Inhibition de mapk p38 pour le traitement du cancer
EP3432927A4 (fr) Inhibiteurs trispécifiques pour le traitement du cancer
EP3570844A4 (fr) Azolopyrimidine pour le traitement de troubles liés au cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3400010A4 (fr) Combinaisons anti-her2 pour le traitement des tumeurs
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3665482A4 (fr) Ciblage de kinases pour le traitement de métastases cancéreuses
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP3503887A4 (fr) Combinaisons pour le traitement du cancer
EP3411073A4 (fr) Combinaisons pour le traitement du cancer
MA51613A (fr) Polythérapie pour le traitement ou la prévention du cancer
EP3990458A4 (fr) Composés pour le traitement du cancer
MA54559A (fr) Polythérapie pour le traitement du cancer
EP3442564A4 (fr) Composition de proenzymes pour le traitement du cancer
EP3849544A4 (fr) Polythérapie pour le traitement du cancer de la prostate
EP3793548A4 (fr) Composés pour le traitement du cancer du pancréas